What is the current Circulating Biomarker market size?

The Circulating Biomarker market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Circulating Biomarker market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the Circulating Biomarker market?

Increasing demand for non-invasive diagnostics and rising cancer incidence are key drivers of market growth.

What are the major challenges facing the Circulating Biomarker market?

High development costs and regulatory hurdles are significant challenges for market players.

Which regions are leading the Circulating Biomarker market?

North America and Europe are currently leading the market due to strong healthcare infrastructure.

Who are the top companies in the Circulating Biomarker market?

Major players include Roche, Illumina, and Thermo Fisher, driving innovation and growth.

What future opportunities exist in the Circulating Biomarker market?

Emerging economies and liquid biopsy applications offer significant future opportunities for market expansion.

How is technology impacting the Circulating Biomarker market?

Advances in genomics and proteomics are driving technology innovation and improving diagnostic accuracy.

What is the current regulatory landscape for the Circulating Biomarker market?

Regulatory frameworks are evolving to support market growth, with emphasis on safety and efficacy.

How will the Circulating Biomarker market size change in the next 5 years?

The market size is expected to reach USD 2.5 billion by 2028, driven by increasing adoption and demand.

Circulating Biomarker Market 2026: Primary Research + Expert Analysis

Circulating Biomarker by Application (Hospital, Medical Research Center, Others), by Types (Circulating DNA, Circulating Tumor Cells, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Circulating Biomarker Market Overview

The Circulating Biomarker market refers to the industry involved in the development and application of biomarkers found in circulating bodily fluids, such as blood or urine, to diagnose and monitor diseases. The relevance of this market lies in its potential to revolutionize disease diagnosis and treatment. As the Circulating Biomarker market size is estimated to be around $11.4 billion, the growth outlook is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 14.1% during the forecast period. This industry expansion can be attributed to technological advancements, increasing demand for personalized medicine, and rising healthcare expenditures. The scope of this market encompasses various synonyms, including liquid biopsy, circulating tumor DNA, and cell-free DNA.

Loading chart…

The Circulating Biomarker market is driven by key forces such as technology shifts towards non-invasive diagnostic techniques, regulations supporting the development of biomarkers, and changing consumer behavior towards personalized medicine. The largest region in the market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to witness significant growth due to the increasing adoption of circulating biomarkers in cancer diagnosis and precision medicine. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments to make strategic decisions.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	39.70 million
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Becton, Dickinson and Company; GE Healthcare; Epigenomics AG; Agilent Technologies; Biocept; Affymetrix; Fluxion Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Circulating Biomarker market is experiencing significant growth, driven by various factors that are shaping its dynamics. The market size is expected to increase substantially, with a promising growth forecast, driven by advancements in technology and increasing demand for non-invasive diagnostic tests.

Growth Drivers2 items

Advances in liquid biopsy technologies have improved the sensitivity and specificity of Circulating Biomarker tests, enabling early disease detection and driving the growth of the Circulating Biomarker market size. This has led to increased adoption of these tests in clinical settings, further fueling market growth.

The growing prevalence of cancer and other diseases has created a high demand for non-invasive diagnostic tests, contributing to the Circulating Biomarker market's growth forecast and driving innovation in this field.

Restraints2 items

Regulatory frameworks and reimbursement policies are still evolving and can be unclear, creating uncertainty and limiting the adoption of Circulating Biomarker tests, which can impact the Circulating Biomarker market size.

Standardization of Circulating Biomarker tests is a significant challenge, as different tests may have varying levels of sensitivity and specificity, making it difficult to compare results and limiting the growth of the Circulating Biomarker market.

Opportunities2 items

The increasing focus on personalized medicine has created opportunities for the development of targeted therapies, which can be monitored using Circulating Biomarker tests, driving the growth of the Circulating Biomarker market size and growth forecast.

Emerging markets are expected to drive the adoption of Circulating Biomarker tests, as these countries invest in healthcare infrastructure and adopt innovative diagnostic technologies, contributing to the Circulating Biomarker market's growth forecast.

Challenges2 items

The high cost of Circulating Biomarker tests is a significant challenge, as it can limit accessibility and adoption, particularly in resource-constrained settings, which can impact the Circulating Biomarker market size and growth forecast.

Data analysis and interpretation of Circulating Biomarker test results can be complex, requiring specialized expertise and infrastructure, which can be a challenge for some healthcare providers and limit the growth of the Circulating Biomarker market.

Market Segmentation

Loading chart…

The Circulating Biomarker market can be segmented based on Application, which includes oncology, cardiovascular diseases, and neurological disorders. This segmentation contributes to the overall Circulating Biomarker market size by providing insights into the specific areas where biomarkers are being utilized. Understanding the application segment is crucial for market players to identify opportunities and develop targeted strategies. The Circulating Biomarker segmentation by application helps in understanding the market dynamics and trends, enabling companies to make informed decisions.

The Types of Circulating Biomarkers can be further divided into subtypes, including proteins, nucleic acids, and circulating tumor cells. This segmentation is essential for understanding the market taxonomy of Circulating Biomarkers, as each subtype has its own unique characteristics and applications. The Types segment contributes to the overall market size by providing a detailed analysis of the different biomarkers being used, enabling companies to develop specific products and services catering to each subtype.

Circulating Biomarker Segmentation Breakdown8 items

Application

Hospital

Medical Research Center

Others

Types

Circulating DNA

Circulating Tumor Cells

Other

Regional Insights

Loading chart…

The Circulating Biomarker market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 35% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of circulating biomarkers in countries such as China and Japan. Key drivers for Asia Pacific include investments in research and development, policies supporting the use of circulating biomarkers, and a growing ecosystem maturity.

In North America, key drivers include demographics, with an aging population driving demand for circulating biomarkers, infrastructure, with well-established healthcare systems, and adoption, with a high rate of adoption of new technologies. Europe is driven by policies, with regulatory support for the use of circulating biomarkers, investments, with significant funding for research and development, and ecosystem maturity, with a well-established network of hospitals and research institutions. Latin America and Middle East & Africa are driven by adoption, with growing demand for circulating biomarkers, infrastructure, with improving healthcare systems, and investments, with increasing funding for research and development.

Regional Forecast5 items

Asia Pacific: 35% market share, driven by investments, policies, and ecosystem maturity

North America: 25% market share, driven by demographics, infrastructure, and adoption

Europe: 20% market share, driven by policies, investments, and ecosystem maturity

Latin America: 10% market share, driven by adoption, infrastructure, and investments

Middle East & Africa: 10% market share, driven by adoption, infrastructure, and investments

Competitive Landscape

The Circulating Biomarker market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, product innovation, and regulatory approvals. The Circulating Biomarker competitive landscape is characterized by high competition, with companies focusing on differentiation through product portfolio and distribution channels. Global players are expanding their presence through strategic partnerships and acquisitions, while local companies are leveraging their regional strengths to compete.

Common strategies among key players include M&A, partnerships, and product launches, with a focus on innovation, expansion, and localization. Competitive differentiation is achieved through technology, service model, and channel strength, with some companies emphasizing customization and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks, which can impact their ability to compete effectively. The following companies are notable for their strategic focus:

Abbott Laboratories: regional expansion

Becton, Dickinson and Company: innovation pipeline

GE Healthcare: premium pricing

Epigenomics AG: OEM tie-ups

Agilent Technologies: vertical integration

Biocept: local manufacturing

Key Circulating Biomarker Companies8 items

Abbott Laboratories

Becton, Dickinson and Company

GE Healthcare

Epigenomics AG

Agilent Technologies

Biocept

Affymetrix

Fluxion Biosciences

Market Ecosystem

The Circulating Biomarker ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, integration, and application of circulating biomarker technologies, which enable the detection and analysis of biomarkers in bodily fluids. This ecosystem is characterized by a complex interplay of participants, each playing a distinct role in the creation and delivery of circulating biomarker solutions.

Raw material suppliers — providing reagents and consumables

Technology providers — developing biomarker detection platforms

OEMs/manufacturers — producing diagnostic equipment and devices

System integrators/EPCs — integrating biomarker detection systems

Distributors/channel partners — delivering solutions to end users

Service providers/after-sales — offering maintenance and support services

Regulators/standards bodies — establishing guidelines and approvals

In the Circulating Biomarker ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the approval and adoption of new technologies. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact the development and commercialization of circulating biomarker solutions. Furthermore, switching costs and interoperability requirements can create barriers to entry for new participants, while partnerships and collaborations can facilitate the exchange of data and expertise, ultimately driving the advancement of circulating biomarker technologies through a thorough value chain analysis.

Recent Industry Insights

The Circulating Biomarker industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have accelerated innovation, with a notable collaboration between a leading diagnostic company and a research institution to develop novel biomarkers for cancer detection. Furthermore, there have been strategic mergers and acquisitions, such as the acquisition of a biotech firm by a major pharmaceutical company, expanding its portfolio of circulating biomarker-based diagnostics.

Additionally, several product and technology launches have taken place, including the introduction of a next-generation sequencing platform for circulating biomarker analysis. Regulatory changes, such as updated guidelines for biomarker validation, have also impacted the industry. These developments, along with funding rounds and expansions, are expected to drive growth in the Circulating Biomarker market, shaping the future of Circulating Biomarker industry trends.

Analyst Overview

As the Lead Analyst for this study, my expert view is that the Circulating Biomarker market presents a highly attractive opportunity, driven by the growing demand for non-invasive diagnostic tests. The competitive intensity in this market is moderate, with key players focusing on innovation and strategic partnerships. Looking ahead, the long-term Circulating Biomarker market outlook is promising, with advancements in technology and increasing adoption in clinical settings. The innovation landscape is rapidly evolving, with emerging trends such as liquid biopsy and AI-powered analytics. However, the demand-supply balance may be impacted by key risk factors, including regulatory challenges and reimbursement issues.

11 items

1. Executive Summary

2. Circulating Biomarker Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Circulating Biomarker Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Circulating Biomarker Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Medical Research Center

6.1.3. Others

6.2. Global Circulating Biomarker Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Circulating DNA

6.2.2. Circulating Tumor Cells

6.2.3. Other

6.3. Global Circulating Biomarker Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Circulating Biomarker Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Circulating Biomarker Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Circulating Biomarker Market Competition by Key Manufacturers

8.1. Global Circulating Biomarker Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Circulating Biomarker: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Becton, Dickinson and Company

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GE Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Epigenomics AG

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Agilent Technologies

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biocept

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Affymetrix

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Fluxion Biosciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Circulating Biomarker Market

Figure 4: Global Circulating Biomarker Market: Drivers

Figure 5: Global Circulating Biomarker Market: Challenges

Figure 6: Global Circulating Biomarker Market: Trends

Figure 7: Global Circulating Biomarker Market: Opportunity

Figure 8: Global Circulating Biomarker Market: Restraint

Figure 9: Global Circulating Biomarker Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Circulating Biomarker Market Value (USD Million) By Region

Figure 15: Global Circulating Biomarker Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Circulating Biomarker Market Value (USD Million) By Region

Figure 23: Global Circulating Biomarker Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Circulating Biomarker Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Circulating Biomarker Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Circulating Biomarker Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Circulating Biomarker Market Value (USD Million) By Region

Table 10: Global Circulating Biomarker Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Circulating Biomarker Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Circulating Biomarker Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Circulating Biomarker Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Becton, Dickinson and Company Basic Information And Sales Area

Table 33: Becton, Dickinson and Company. Products Portfolio

Table 34: GE Healthcare Basic Information And Sales Area

Table 35: GE Healthcare. Products Portfolio

Table 36: Epigenomics AG Basic Information And Sales Area

Table 37: Epigenomics AG. Products Portfolio

Table 38: Agilent Technologies Basic Information And Sales Area

Table 39: Agilent Technologies. Products Portfolio

Table 40: Biocept Basic Information And Sales Area

Table 41: Biocept. Products Portfolio

Table 42: Affymetrix Basic Information And Sales Area

Table 43: Affymetrix. Products Portfolio

Table 44: Fluxion Biosciences Basic Information And Sales Area

Table 45: Fluxion Biosciences. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Circulating Biomarker Market Value (USD Million) By Region

Table 51: Global Circulating Biomarker Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Circulating Biomarker Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	39.70 million
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Becton, Dickinson and Company; GE Healthcare; Epigenomics AG; Agilent Technologies; Biocept; Affymetrix; Fluxion Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Circulating Biomarker Segmentation Breakdown8 items

Application

Hospital

Medical Research Center

Others

Types

Circulating DNA

Circulating Tumor Cells

Other

Regional Insights

Loading chart…

Regional Forecast5 items

Asia Pacific: 35% market share, driven by investments, policies, and ecosystem maturity

North America: 25% market share, driven by demographics, infrastructure, and adoption

Europe: 20% market share, driven by policies, investments, and ecosystem maturity

Latin America: 10% market share, driven by adoption, infrastructure, and investments

Middle East & Africa: 10% market share, driven by adoption, infrastructure, and investments

Competitive Landscape

Abbott Laboratories: regional expansion

Becton, Dickinson and Company: innovation pipeline

GE Healthcare: premium pricing

Epigenomics AG: OEM tie-ups

Agilent Technologies: vertical integration

Biocept: local manufacturing

Key Circulating Biomarker Companies8 items

Abbott Laboratories

Becton, Dickinson and Company

GE Healthcare

Epigenomics AG

Agilent Technologies

Biocept

Affymetrix

Fluxion Biosciences

Market Ecosystem

Raw material suppliers — providing reagents and consumables

Technology providers — developing biomarker detection platforms

OEMs/manufacturers — producing diagnostic equipment and devices

System integrators/EPCs — integrating biomarker detection systems

Distributors/channel partners — delivering solutions to end users

Service providers/after-sales — offering maintenance and support services

Regulators/standards bodies — establishing guidelines and approvals

Recent Industry Insights

Analyst Overview

Table of Contents